Ohio State Navbar

News


Long Noncoding RNAs: A Novel Prognostic Marker in Older Patients With AML


March 31, 2015

A study led by researchers at the OSUCCC – James describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML). AML occurs mainly in older patients and has a three-year survival rate of 5 to 15 percent. The study is published online in the Proceedings of the National Academy of Sciences. Clara D. Bloomfield, MD, a Distinguished University Professor who also serves as OSU cancer scholar and senior adviser to the OSUCCC – James, was principal investigator. Ramiro Garzon, MD, associate professor of internal medicine at Ohio State and member of the Leukemia Research Program at the OSUCCC – James, was first author. The rest of the story



BMT Nurses Win National Award for Patient Care Excellence


March 31, 2015

Nurses with the Blood and Marrow Transplant (BMT) Program at the OSUCCC – James have received national recognition for exceptional patient care and professional nursing practice with a three-year, bronze level Beacon Award for Excellence™ from the American Association of Critical-Care Nurses (AACN). The OSUCCC – James is the first BMT unit in the country to earn Beacon Award for Excellence recognition. The team includes 75 nurses. The rest of the story



$1.59 Million Grant Awarded


March 31, 2015

A team led by PIs Michael A. Caligiuri, MD, and Jianhua Yu, PhD, will use a five-year, $1.59 million grant to study how a dietary component from edible plants enhances the immune system’s ability to prevent AML or its recurrence. Caligiuri is director of the OSUCCC and CEO of The James. Yu is an assistant professor in the Division of Hematology and a member of the MCC Program. This project is a collaboration with co-investigator A. Douglas Kinghorn, PhD, DSc, a professor in the College of Pharmacy at Ohio State and member of the MCC Program. The rest of the story



STATE'S 2015 ASH REVIEW SLATED FOR JAN. 30


January 09, 2015

STATE'S 2015 ASH REVIEW SLATED FOR JAN. 30 The rest of the story



NEW JAMES OPEN FOR BUSINESS AND RUNNING SMOOTHLY


January 09, 2015

NEW JAMES OPEN FOR BUSINESS AND RUNNING SMOOTHLY The rest of the story



An Up-and-Coming Superstar!


November 04, 2014

Ashley Rosko, MD, an assistant professor in the Division of Hematology at Ohio State and a member of the Cancer Control Program at the OSUCCC – James, has received one of five Young Investigator Awards presented by the National Comprehensive Cancer Network (NCCN) Foundation. The Foundation annually awards these grants – each worth $150,000 over two years – to young investigators at NCCN member institutions who are dedicated to advancing and discovering treatments for cancer, enhancing quality and improving education. The awardees submitted grant proposals that were reviewed by a multidisciplinary panel of oncology experts who judged them on several components, including scientific merit and study design. Dr. Rosko’s funded project is “NCCN Senior Adult Oncology: Myeloma Comprehensive Geriatric Assessment and Biomarkers of Aging Investigation.” The OSUCCC – James is a charter member of the NCCN, a not-for-profit alliance of 25 of the world’s leading cancer centers. The alliance is dedicated to improving the quality and effectiveness of care provided to patients with cancer. The rest of the story



Health Care Heroes Recognized - John C. Byrd, Honorable Mention


July 17, 2014

Columbus Business First recognized the honorees for its Health Care Heroes Awards during an event Thursday morning. The rest of the story



Ohio State Hematologist Regcognized Nationally


April 14, 2014

John Byrd has again received national scientific recognition for his translational research investigating use of the drug, ibrutinib, in the treatment of chronic lymphocytic leukemia, at the 2014 Clinical Research Forum’s third annual Top 10 Research Achievement Awards. Byrd is hematology division director and co-leader of the Leukemia Research Program at Ohio State’ Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute (OSUCCC – James.) The rest of the story



John C. Byrd, MD, Director of the Division of Hematology Honored


March 06, 2014

John C. Byrd, MD, director of the Division of Hematology at Ohio State and co-leader of the Leukemia Research Program at the OSUCCC – James, has been named associate editor of the journal Blood, which is the official publication of the American Society of Hematology (ASH) and one of the premier publications in the field. “This is truly an honor and a reflection of the high esteem that Dr. Byrd has earned in our academic discipline,” says Michael Grever, MD, professor and chair of the Department of Internal Medicine at Ohio State and co-leader of the Leukemia Research Program at the OSUCCC – James. “This well-deserved honor will reflect highly upon Ohio State and our comprehensive cancer center.” Byrd is a professor of Medicine, of Medicinal Chemistry and of Veterinary Biosciences at Ohio State, where he also holds the D. Warren Brown Designated Chair in Leukemia Research. The rest of the story



Study Identifies Possible Target For Future Brain Cancer Drugs


March 06, 2014

A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at the OSUCCC – James. The findings were published in the journal Cancer Research. Robert Baiocchi, MD, PhD, associate professor of medicine at Ohio State and a hematologist at the OSUCCC – James, was co-corresponding author. The rest of the story



Previous     Next